Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 10, 2003, Pages 1341-1347

  Weiner, Marc ^a   Burman, William ^b   Vernon, Andrew ^b   Benator, Debra ^b   Peloquin, Charles A ^b   Khan, Awal ^b   Weis, Stephen ^b   King, Barbara ^b   Shah, Nina ^b   Hodge, Thomas ^b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

Isoniazid; Pharmacokinetics; Rifapentine; Treatment; Tuberculosis

Indexed keywords

ACYLTRANSFERASE; ISONIAZID; ISOPROTEIN; RIFAMPICIN; RIFAPENTINE;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CONCENTRATION; DRUG HALF LIFE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOW DRUG DOSE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEROLOGY; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV SERONEGATIVITY; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; RECURRENCE; REFERENCE VALUES; RIFAMPIN; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0037614780     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200208-951OC     Document Type: Article

References (27)

1. Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, Morris JS, Mitchison DA. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Am J Respir Crit Care Med 1998;157:1726-1733.
2. Package insert, Rifapentine (Priftin). Data on file. Hoechst Marion Roussel Inc. Kansas City, MO; 1998.
3. Tuberculosis Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons. Lancet 2002;360:528-534.
4. Vernon A, Burman W, Benator D, Khan A, Bozeman L for the Tuberculosis Trials Consortium. Acquired rifamycin mono-resistance among patients with HIV-related tuberculosis treated with supervised once weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847.
5. Long M, Snider D, Farer L. US Public Health Service Cooperative Trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-894.
6. Weiner M, Khan A, Benator D, Peloquin C, Burman W, and the TB Trials Consortium. Low isoniazid levels are associated with TB treatment failure/relapse with once-weekly rifapentine and isoniazid [abstract]. Am J Respir Crit Care Med 2001;163:A498.
7. Weiner M, Khan A, Benator D, Peloquin C, Burman W, and the TB Trials Consortium. Low isoniazid levels are associated with TB treatment failure/relapse with once-weekly rifapentine and INH [abstract]. Int J Tuberc Lung Dis 2001; 5 (Suppl 1): S120.
8. Burman W, Vernon A, Benator D for the Tuberculosis Trials Consortium. Isoniazid, rifampin, and rifapentine in human plasma: no need to add ascorbic acid to maintain stability [abstract]. Am d Respir Crit Care Med 1999;159:A496.
9. Cascorbi I, Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999;9:123-127.
10. Acocella G, Nonis A, Pernia G, Patane E, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampin and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily in antituberculosis chemotherapy II: two-month, daily administration study. Am Rev Respir Dis 1988;138:886-888.
11. Keung A, Reith K, Eller MG, McKenzie KA, Cheng L, Weir SJ. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Int J Tuberc Lung Dis 1999;3:426-436.
12. Keung A, Eller MG, McKenzie KA, Weir SJ. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int J Tuberc Lung Dis 1999;5:437-444.
13. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food and with antacids. Int J Tuberc Lung Dis 1999;3:703-710.
14. Peloquin CA, Jaresko GS, Chan-Loi Y, Keung ACF, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin and pyrazinamide. J Antimicrob Chemother 1997;41:2670-2679.
15. Pharsight Corporation. WinNonlin Version 3.0. Examples Guide. Pharsight Corporation, Mountain View, CA; 1998
16. Tam CM, Chan SL, Kam KM, Sim E, Staples D, Sole KM, Al-Ghusein H, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen: interim report: no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis 2000;4:262-267.
17. Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen: final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002;6:3-10.
18. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. Am Rev Respir Dis 1977;116:807-820.
19. Daniel N, Lounis B, Ji B, O'Brien R, Vernon A, Geiter L, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice: long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med 2000;161:1572-1577.
20. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G. Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-3486.
21. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ 1970;43:143-206.
22. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis. Tubercle 1973;54:23-45.
23. Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;120:1520-1524.
24. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-1183.
25. Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, Perkins MD, Joloba M, Namale A, Johnson JL, Texeira L, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2600-2606.
26. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999:115:12-18.
27. Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, Mosher A, Samuels M, Vernon A. Tuberculosis Trials Consortium: a prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002;165:1526-1530.